



Target Validation Using Genomics and Informatics

EMBL–WELLCOME GENOME CAMPUS CONFERENCE

WELLCOME GENOME CAMPUS
CONNECTING
SCIENCE
ADVANCED
COURSES+
SCIENTIFIC
CONFERENCES

We have moved our website to embl.org/events. The content below is no longer being updated.

EMBL Courses and Conferences during the Coronavirus pandemic

With the onsite programme paused, many of our events are now being offered in virtual formats.

Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.

More information for participants of events at EMBL Heidelberg can be found [here](#).

Programme

Got something to say? Tweet it! [#EWGtarget](#)

[HIDE ALL](#)

Day 1 - Sunday 8 December 2019

Time	Speaker
14:00 - 15:00	Arrival and Registration with light refreshments
15:00 - 15:15	Opening remarks

Time	Speaker
	Keynote speaker
15:15 - 16:00	FinnGen: a public-private partnership to mine genomics and health data for new paths to therapy Mark Daly - Institute for Molecular Medicine Finland FIMM, Finland
16:00 - 19:00	Session 1 - Genetics Chair: Jeff Barrett - Genomics plc, UK
16:00 - 16:30	Translating immune disease GWAS variants to causal cell types and genes Gosia Trynka - Wellcome Sanger Institute, UK
16:30 - 16:45	Human loss-of-function variants in >4 million individuals suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson's disease Nicola Whiffin - Imperial College London, UK
16:45 - 17:00	Inhibition of angiotensinogen as a therapeutic strategy for lowering blood pressure: a Mendelian randomization study Jonas Bovijn - University of Oxford, UK
17:00 - 17:30	Big data meets drug discovery Astrid Ruefli-Brasse - 23andMe, USA
17:30 - 18:00	Coffee Break and Meet the Speakers
18:00 - 18:30	Guiding targets to success: Experiences progressing genetically validated targets through discovery and development Janna Hutz - Eisai Center for Genetics Guided Dementia Discovery, USA
18:30 - 18:45	Evaluating genetic support for lipid-modifying drug targets Maria - Gordillo-Maranon, University College London, UK
18:45 - 19:00	A phenome-wide gene-based collapsing analysis of rare loss-of-function and missense variation in 136,508 UK Biobank exomes Slavé Petrovski - AstraZeneca, UK
19:00 - 20:00	Dinner
20:00 - 22:00	Poster Session 1 (odd numbers)

Day 2 - Monday 9 December 2019

Time	Speaker
09:00 - 12:00	Session 2 - Case studies Chair: Sandra Engle - Biogen, USA

Time	Speaker
09:00 - 09:30	Functional genetics and genomics cross-comparisons between immune-mediated diseases Calliope Dendrou - Wellcome Trust Centre for Human Genetics, UK
09:30 - 10:00	From SNPs to biology in autoimmune disease James Lee - University of Cambridge, UK
10:00 - 10:15	A cross-disciplinary, integrative approach to target prioritization Katrina de Lange - Novartis, Switzerland
10:15 - 10:30	Identification of a candidate for breast cancer risk prevention Jonathan Beesley- QIMR BERGHOFER, Australia
10:30 - 11:00	Coffee Break and Meet the Speakers
11:00 - 11:30	Genomics and Target Validation in Alzheimer's disease Damien Crowther - AstraZeneca, UK
11:30 - 11:45	Investigating the causal relationship between glaucoma and Alzheimer's disease: a mendelian randomization study Ashley Budu-Aggrey- University of Bristol, UK
11:45 - 12:00	Investigating calcium channel isoforms to identify novel, genomically-informed treatment targets for psychiatric disorders Nicola Hall - University of Oxford, UK
12:00 - 13:30	Lunch
13:30 - 16:30	Session 3 - Genome editing for target validation Chair: Gitte Neubauer - Cellzome, Germany
13:30 - 14:00	Advanced CRISPR applications in primary human T cells Eric Shifrut - University of California, San Francisco, USA
14:00 - 14:15	Unbiased compound-target interface mapping by forward genetics Moritz Horn - Acus Laboratories GmbH, Germany
14:15 - 14:30	Target discovery through functional genomics Samantha Peel - Astrazeneca, UK
14:30 - 15:00	Modeling disease biology with human stem cell-derived cells and genomic editing to enable drug discovery Sandra Engle - Biogen, USA
15:00 - 15:30	Coffee Break and Meet the Speakers
15:30 - 16:00	Mapping gene regulation with large-scale cellular genetic screens Silvia Domcke - University of Washington, USA

Time	Speaker
16:00 - 16:15	CRISPR/Cas9 functional screens for long non-coding RNAs in lung cancer Taisia Polidori - University of Bern, Switzerland
16:15 - 16:30	Functional insights and enhanced target identification through co-essentiality Martino Colombo - Celgene Research, Spain
16:30 - 18:30	Poster Session 2 (even numbers)
18:45	Buses depart to Christmas market and hotels

Day 3 - Tuesday 10 December 2019

Time	Speaker
09:00 - 11:45	Session 4 - Relevant models for target validation Chair: Gosia Trynka - Wellcome Sanger Institute, UK
09:00 - 09:30	Understanding mechanisms of resistance: novel targets for cancer treatment Dirk Jäger - National Center for Tumor Diseases, Germany
09:30 - 09:45	Functional genomic follow-up of GWAS to identify novel drug targets for endometrial cancer Dylan Glubb - QIMR Berghofer Medical Research Institute, Australia
09:45 - 10:00	Functional genomic analysis uncovers mitophagy regulators associated with Parkinson's disease risk Daniela Melandri - University College London, UK
10:00 - 10:30	Organoid biobanks combine genetic and functional patient and disease data Robert Vries - Hubrecht Organoid Technology, The Netherlands
10:30 - 11:00	Coffee Break and Meet the Speakers
11:00 - 11:15	Systematic prioritisation of genes at all GWAS trait-associated loci Edward Mountjoy - Wellcome Sanger Institute, UK
11:15 - 11:45	Learning the manifold of human disease with the aim to establish a new approach to drug discovery Paolo Casale - insitro, USA
11:45 - 13:15	Lunch
13:15- 16:15	Session 5 - Computational methods and analysis Chair: Oliver Stegle - EMBL Heidelberg, Germany

Time	Speaker
13:15 - 13:45	Using genomics to evaluate T-cell therapeutic targets Hans Bitter - bluebird bio, USA
13:45 - 14:00	Genetic drug target validation using Mendelian randomization Amand Schmidt - University College London, UK
14:00 - 14:15	Network and pathway analysis of GWAS for target identification Alex Gutteridge - GSK, UK
14:15 - 14:45	Therapeutic target identification through the inference of pathogenic cells and tissues Jeff Barrett - Genomics plc, UK
14:45 - 15:15	Coffee Break and Meet the Speakers
15:15 - 15:30	Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets Hendrik Weisser - STORM Therapeutics, UK
15:30 - 15:45	Reconciling GWAS and Mendelian genetics through core-gene identification Patrick Deelen - University Medical Center Groningen, The Netherlands
15:45 - 16:30	Keynote speaker Relevant phenotypic screens in complex systems Edith Hessel - GSK, UK
16:30 - 16:45	Closing remarks and poster prize
17:00	Buses depart to downtown and airport